Copyright ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Nov 28, 2017; 9(33): 1239-1252
Published online Nov 28, 2017. doi: 10.4254/wjh.v9.i33.1239
Global elimination of hepatitis C virus infection: Progresses and the remaining challenges
Reza Taherkhani, Fatemeh Farshadpour
Reza Taherkhani, Fatemeh Farshadpour, the Persian Gulf Tropical Medicine Research Center, Bushehr University of Medical Sciences, Bushehr 7514633341, Iran
ORCID number: Reza Taherkhani (0000-0001-6499-0531); Fatemeh Farshadpour (0000-0002-8317-9573).
Author contributions: Farshadpour F designed the study and wrote the manuscript; Taherkhani R provided the literature review and edited the manuscript and was also involved in designing the study.
Conflict-of-interest statement: The authors declared that they do not have anything to disclose regarding funding or conflict of interest with respect to this manuscript.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Correspondence to: Fatemeh Farshadpour, PhD, the Persian Gulf Tropical Medicine Research Center, Bushehr University of Medical Sciences, Moallem Street, Bushehr 7514633341, Iran.
Telephone: +98-917-1712653
Received: July 15, 2017
Peer-review started: July 19, 2017
First decision: August 15, 2017
Revised: September 1, 2017
Accepted: September 16, 2017
Article in press: September 16, 2017
Published online: November 28, 2017


Today, with the introduction of interferon-free direct-acting antivirals and outstanding progresses in the prevention, diagnosis and treatment of hepatitis C virus (HCV) infection, the elimination of HCV infection seems more achievable. A further challenge is continued transmission of HCV infection in high-risk population specially injecting drug users (IDUs) as the major reservoir of HCV infection. Considering the fact that most of these infections remain undiagnosed, unidentified HCV-infected IDUs are potential sources for the rapid spread of HCV in the community. The continuous increase in the number of IDUs along with the rising prevalence of HCV infection among young IDUs is harbinger of a forthcoming public health dilemma, presenting a serious challenge to control transmission of HCV infection. Even the changes in HCV genotype distribution attributed to injecting drug use confirm this issue. These circumstances create a strong demand for timely diagnosis and proper treatment of HCV-infected patients through risk-based screening to mitigate the risk of HCV transmission in the IDUs community and, consequently, in the society. Meanwhile, raising general awareness of HCV infection, diagnosis and treatment through public education should be the core activity of any harm reduction intervention, as the root cause of failure in control of HCV infection has been lack of awareness among young drug takers. In addition, effective prevention, comprehensive screening programs with a specific focus on high-risk population, accessibility to the new anti-HCV treatment regimens and public education should be considered as the top priorities of any health policy decision to eliminate HCV infection.

Key Words: Hepatitis C virus, Epidemiology, Elimination, Injecting drug user, Prevention, Vaccine, Diagnosis, Treatment

Core tip: Despite the outstanding progresses in the management of hepatitis C virus (HCV) infection, the elimination of HCV would be difficult due to the emergence of injection drug use as the main source of HCV transmission. Asymptomatic nature of HCV infection, restricted accessibility to diagnostic approaches and appropriate antiviral treatments in the injecting drug users (IDUs) community are the root cause of failure in control of HCV infection among IDUs. These circumstances create a strong demand for timely diagnosis and proper treatment of HCV-infected patients as well as raising general awareness of HCV infection through public education to mitigate the risk of HCV transmission.


With a global prevalence rate of 2.8%, equating to over 185 million infections, and more than 350000 deaths annually, hepatitis C virus (HCV) infection is undoubtedly considered a major public health problem[1]. Globally, an estimated 3 million to 4 million new cases of HCV infection emerge every year[1]. Furthermore, the HCV-related mortality is increasing and HCV infection is projected to be the most important leading cause of viral hepatitis-related mortality in the near future[1,2]. Apparently, the management of HCV infection faces several challenges. These challenges merit further attention if elimination of HCV infection is aimed to be achieved.


HCV is a member of the family Flaviviridae and the genus Hepacivirus. The HCV genome is a positive-stranded RNA, which encodes a core protein (C), two envelope glycoproteins (E1 and E2), and several non-structural proteins (NS1, NS2, NS3, NS4A, NS4B, NS5A and NS5B)[3,4]. This enveloped positive-stranded RNA virus is usually acquired through exposure to infected blood. This might happen through transfusion of blood and blood products, surgery, organ transplantation, intravenous drug use, tattooing, hemodialysis, unsafe injection practices, mother to fetus, and sexual intercourse[5-8]. However, sexual transmission of HCV is less common and most often observed among men who have sex with men and HIV-infected patients[9,10].

HCV is the causative agents of hepatitis C infection. This infection is characterized by an acute or chronic course in the host. The complications are preliminary asymptomatic, mild or severe, which spontaneously clear or slowly progress to chronic liver disease, cirrhosis and finally hepatocellular carcinoma (HCC) within about 20 years[11,12]. The clinical symptoms of acute HCV infection might include fever, fatigue, malaise, and gastrointestinal symptoms such as anorexia, nausea, vomiting, right upper quadrant pain, dark urine, grey-colored stool, and yellow skin and sclera of the eyes, the well-characterized symptoms of jaundice. These symptoms might appear from 3 to 12 wk after being infected. The clinical symptoms of chronic HCV infection might take decades to develop, and they are usually indicative of an advanced liver disease[13-15].

The long-term chronic HCV infection is capable of causing some extra hepatic manifestations with serious consequences, such as glomerulonephritis, diabetes mellitus, thyroid disorders, porphyria cutaneous tarda, mixed cryoglobulinemia, lichen planus, and B cell lymphoproliferative disorders[16-21]. These extrahepatic complications might outshine the hepatic manifestations of HCV infection, and the presence of HCV infection might be overlooked, paving the way for the silent development of advanced liver disease. Therefore, the possible role of HCV in the development of extrahepatic manifestations merits further attention.

Due to genomic heterogeneity, there are 7 major genotypes and over 67 subtypes of HCV[1,22,23]. HCV genotype distribution varies by the route of transmission and geographical location[24,25]. In addition, pathogenicity, response to antiviral therapy and the duration of treatment can be influenced by different HCV genotypes[5,24,26]. The genotypes 1, 2 and 3 show a widespread distribution in almost all parts of the world. HCV genotype 4 has been traditionally restricted to a few countries in the Middle East and Africa and is more prevalent in Saudi Arabia, Bahrain, Jordan, Egypt and Ethiopia[1,27,28]. HCV genotype 5, 6 and 7 have been reported in South Africa, South East Asia and Central Africa, respectively[11,29,30] (Figure 1).

Figure 1
Figure 1 Geographical distribution of hepatitis C virus genotypes. Hepatitis C virus (HCV) genotypes 1, 2 and 3 show a widespread distribution in almost all parts of the world. HCV genotype 4 has been restricted to a few countries in the Middle East and Africa. HCV genotype 5, 6 and 7 have been reported in South Africa, South East Asia and Central Africa, respectively[1,11,30,35,36].

Genotype 1 is more prevalent among patients with history of blood and blood products transfusion, surgery, and dental procedure[24,25,27]. Infection with HCV genotype 2 is mainly associated with nosocomial transmission and prior dental treatment[1,22]. Genotype 3 is frequently found in the intravenous drug user communities and in those with history of tattooing and piercing[24,31,32]. Genotype 4 is mainly transmitted through high-risk sexual practices, especially among homosexual males, and intravenous drug use[1,22].

Infection with HCV genotype 3 is associated with a more rapid progression of fibrosis, a higher degree of steatosis, and a higher incidence of cirrhosis and hepatocellular carcinoma[1,22,31,33]. Spontaneous clearance is more often observed in infection with HCV genotype 1, while if patients remain HCV RNA positive, the disease progresses in a more aggressive manner than the other genotypes[11]. Genotypes 1 and 4 are associated with lower response rates and higher treatment duration in response to interferon (IFN) and ribavirin (RBV) combination therapy as compared to genotypes 2 and 3[6,24,34].


In addition to IFN-based therapies, the direct-acting antivirals (DAAs) have been developed, which specifically inhibit the function of viral proteins that are essential for viral replication[4,37,38]. These DAAs include NS3/4A protease inhibitors, NS5A replication complex inhibitors, nucleoside NS5B polymerase inhibitors, and non-nucleoside NS5B polymerase inhibitors (Table 1)[39-43]. These novel antiviral drugs, despite having considerable advantages over conventional IFN-based therapy, suffer from the resistance-associated mutations, which occur naturally during the replication of the virus and select under the pressure of DAAs. The emergence of HCV resistance-associated variants (RAVs) decreases the susceptibility to DAAs and finally results in treatment failure[38,44-46]. Assessment of resistance substitutions at pretreatment baseline in patients candidate for DAA therapy seems to be the best option to optimize first-line therapeutic strategies, to avoid the fitness of resistant variants as the predominant viral population and to prevent DAA failure due to baseline resistant variants. In addition, failing DAA-based therapy should be discontinued as soon as possible to avoid an increase in the frequency of RAVs, to preserve HCV re-treatment options. Finally, development of next-generation DAAs with higher resistance barrier is strongly recommended[45,47].

Table 1 Profile of direct-acting antiviral agents[4,37,40,42,44,48-78].
Direct-acting antiviral agentGeneric name (abbreviation)Code nameTrade nameActive against HCV genotype (based on clinical trial outcomes)Combination therapy
NS3/4A protease inhibitors (-previr)Telaprevir (TVR)VX-950Incivek/Incivo1TVR + IFN ± RBV
Boceprevir (BOC)SCH-503034 EBP-520Victrelis1BOC + IFN ± RBV
Faldaprevir (FDV)BI-201335-1FDV + Peg-IFN + RBV
Simeprevir (SIM)TMC-435Olysio1 and 4SIM + SOF ± RBV
Vaniprevir (VNV)MK-7009Vanihep1VNV + IFN ± RBV
Asunaprevir (ASV)BMS-650032Sunvepra1 and 4ASV + DCV
Paritaprevir (PTV)ABT-450Veruprevir1 and 4PTV+R+OBV+DAV ± RBV
Voxilaprevir (VOX)GS-9857-Pan-genotypic antiviral activityVOX + SOF + VPR
SovaprevirACH-1625-1Sovaprevir + ODV + RBV
Grazoprevir (GZP)MK-5172-1a, 1b, 4 and 6Zepatier (GZP + EBV)
Danoprevir (DNV)RG-7227-1 and 4DNV + PEG-IFN + RBV
Deldeprevir (DDV)ACH-2684 ACH-0142684-1DDV + ODV
Narlaprevir (NVR)SCH-900518Arlansa1NVR + R + PEG-IFN ± RBV
Vedroprevir (VDV)GS-9451-1VDV + LDV + SOF
Glecaprevir (GLE)ABT-493-Pan-genotypic antiviral activityGLE + PIB ± RBV
-GS-9256-1GS-9256 + PEG-IFN + RBV
GS-9256 + TGV + Peg-IFN ± RBV
NS5A replication complex inhibitors (-Asvir)Daclatasvir (DCV)BMS-790052Daklinza1, 2 and 3Sovodak (DCV + SOF) ± RBV
DCV + VX-135
Ledipasvir (LDV)GS-5885-1, 3, 4, 5 and 6Harvoni (LDV + SOF) ± RBV
LDV + SOF ± (VDV or Radalbuvir)
Ombitasvir (OBV)ABT-267-1 and 4Viekira Pak (OBV + PTV + R + DSV) ± RBV
Technivie (OBV + PTV + R)
Elbasvir (EBV)MK-8742-1a, 1b, 4 and 6Zepatier (EBV + GZP) ± RBV
Velpatasvir (VPR)GS-5816-Pan-genotypic antiviral activityEpclusa (VPR + SOF) ± RBV
Odalasvir (ODV)ACH-3102-1ODV + Sovaprevir + RBV
Ravidasvir (RVD)PPI-668-4RVD + SOF ± RBV
-JNJ-56914845-1GSK2336805 + PEG-IFN + RBV
GSK2336805GSK2336805 + VX-135 + SIM
SamatasvirIDX-18719 IDX-719-1, 2, 3 and 4Samatasvir + SIM + RBV
-BMS-824393-1BMS-824393 + PEG-IFN + RBV
Pibrentasvir (PIB)ABT-530-Pan-genotypic antiviral activityPIB + GLE ± RBV
Ruzasvir (RZR)MK-8408-Pan-genotypic antiviral activityRZR + UPR + GZP
Nucleoside NS5B polymerase inhibitorsSofosbuvir (SOF)PSI-7977;Sovaldi; SoforalPan-genotypic antiviral activitySOF + IFN ± RBV
(-Buvir)GS-7977Sovodak (DCV + SOF) ± RBV
Mericitabine (MCB)RG-7128-1 and 4MCB + PEG-IFN + RBV
RO5024048MCB + DNV
-VX-135-1VX-135 + GSK2336805 + SIM
ALS-2200VX-135 + TVR + RBV
VX-135 + DCV
VX-135 + RBV
VX-135 + SIM
ValopicitabineNM283-1Valopicitabine + Peg-IFN
Non-nucleoside NS5B polymerase inhibitors (-Buvir)Beclabuvir (BCV)BMS-791325-1BCV+ ASV+ DCV
Dasabuvir (DAV)ABT-333Exviera1DAV + OBV+ PTV + R ± RBV
LomibuvirVX-222-1VX-222 + TVR + RBV
VCH-222VX-222 + Filibuvir
FilibuvirPF-00868554,-1Filibuvir + Peg-IFN + RBV
PF-868554Filibuvir + VX-222
Setrobuvir (STV)ANA-598-1STV + IFN + RBV
RO-5466731STV + R + DNV + RBV ± MCB
Nesbuvir (NBV)HCV-796-1NBV +Peg-IFN + RBV
Tegobuvir (TGV)GS-9190-1TGV + GS-9256 +Peg-IFN ± RBV
Deleobuvir (DBV)BI-207127-1DBV + PEG-IFN + RBV
Uprifosbuvir (UPR)MK-3682-Pan-genotypic antiviral activityUPR + RZR
RadalbuvirGS-9669-1Radalbuvir + LDV + SOF
AL-335ALS-335-1AL-335 + ODV + SIM

Telaprevir and boceprevir are not recommended by WHO due to the frequent adverse effects and low cure rates[79].

Prior to the treatment, the infected individuals need to be identified. HCV infection is described by the presence of anti-HCV antibodies and HCV-RNA in plasma or serum with either elevated or normal levels of liver enzymes[29]. Anti-HCV antibodies are detected by using serological screening tests, including enzyme linked immunosorbent assay and recombinant immunoblot assay. Detection of anti-HCV antibodies indicates current or past HCV infection. An additional test called HCV RNA test or reverse transcriptase polymerase chain reaction assay (RT-PCR) is needed to determine if a person is currently infected with HCV[17,80-82].

However, those infected individuals with undetectable levels of HCV-RNA in serum or plasma might remain undiagnosed. In this condition, HCV-RNA can be detected in peripheral blood mononuclear cells (PBMCs) specimens, liver biopsies, and ultracentrifugated serum samples[81,83]. Serological screening tests might be negative or positive in these patients. This kind of infection is defined as occult HCV infection, which is a serious threat to blood safety[84,85]. Since, despite having undetectable level of HCV RNA, blood and blood products are potentially infectious[84,86]. In fact, the presence of blood donors with occult HCV infection can increase the risk of HCV transmission through blood transfusion and therefore is a potential source of HCV transmission in the society[87].

Despite having appropriate antiviral treatments and diagnostic approaches, diagnosis rate and access to treatment is considerably low especially in resource-limited settings. Perhaps the most promising strategy to control HCV infection is the development of a prophylactic vaccine[88,89]. Several vaccine candidates against HCV have been developed so far, including recombinant protein vaccine, peptide-based vaccine, virus-like particles, bacterial-vectored vaccine, viral-vectored vaccine, and DNA vaccine (Table 2)[29,88,90-96]. The currently developed vaccines against HCV, despite inducing strong humoral and cellular immune responses in preclinical animal models or clinical trials in humans, have not been approved for use in human beings[89,90,97]. The reason is high genomic diversity of HCV and viral escape from immune responses[88,90,93,98,99]. Targeting the conserved regions within HCV proteins might help to overcome this genetic variability[100].

Table 2 Vaccine candidates against hepatitis C virus in preclinical and clinical trials.
Type of vaccineVaccine structure/adjuvantStage of developmentOutcomeApplicationDeveloperYearCurrent statusRef.
Recombinant protein vaccineRecombinant E1 or E2/MF597 chimpanzeesInduce strong humoral immune response; complete protection in 5 chimpanzeesProphylactic vaccineChiron/ Novartis1994Completed[101]
Recombinant E1 or E2/Alum4 ChimpanzeesInduce antigen-specific T-helper cytokines in either E1 orTherapeutic vaccineBPRC2011Published[102]
Recombinant E1/AlumPhase I 20 healthy volunteersE2-vaccinated animals; clear HCV infection in only E1-vaccinated animals (neutralizing antibodies) Induce strong cellular and humoral anti-E1 responsesTherapeutic vaccineFujirebio Europe2004Published[103]
Recombinant E1 and E2/MF59Phase I 60 healthy volunteersInduce humoral and cellular immune responsesProphylactic vaccineNovartis2010Completed[104]
Recombinant E1/AlumPhase I/II 20 healthy volunteers and 35 patients with chronic HCV infection/122 HCV-infected patientsInduce HCV specific humoral and cellular immune responses (Th1 type); no change in HCV viral loadTherapeutic vaccineInnogenetics/ GenImmune2003/2008Published[103,105,106]
HCV core protein/ISCOMATRIXPhase I/IIa 30 healthy volunteersInduce strong humoral immune responses in all except one patients; induce CD8+ T cell responses in 2 of 8 patients receiving the highest doseProphylactic vaccineCSL Ltd2009Published[107]
GI5005: Inactivated recombinant Saccharomyces cerevisiae expressing NS3-core fusion protein/ GI-5005 plus SOCPhase I/II 66 patients with chronic HCV infection/Improve SVRTherapeutic vaccineGlobeImmune2009/2010Completed[108,109]
Peptide-based vaccinePeptide from core protein (C35-C44)/ISA51Phase I 26 patients with chronic HCV infectionInduce peptide-specific cellular and humoral immune responses in 15 of 25 patients; decline HCV viral load in 2 of 25 patientsTherapeutic vaccineKarume University2009Published[110]
Four peptides from E1, E2, NS3 and NS5A/Freund’s adjuvantPhase I 12 nonresponder patients with chronic HCV infectionInduce peptide-specific cellular and humoral immune responses; decline HCV viral load in 3 patientsTherapeutic vaccineKarume University2007Published[111]
Autologous dendritic cell delivered six CD8+ T cell epitope peptides from core, NS3 and NS4BPhase I 6 nonresponder patients with chronic HCV infectionInduce transient T-cell responseTherapeutic vaccineBurnet Institute + others2010Completed[112]
IC41: Five peptides from core, NS3, and NS4/Poly-L-argininePhase I/II 128 volunteers/60 non-responders with chronic HCV infectionInduce HCV-specific T-cell responsesTherapeutic vaccineIntercell AG2006/2008Published[113,114]
IC41/Poly-L-arginine + imiquimodPhase I 54 healthy volunteersInduce significant T cell responses; low immunogenicity of topical imiquimodTherapeutic vaccineIntercell AG2010Published[115]
IC41 + imiquimodPhase II 50 HCV-infected patientsDecline viral load; induce T cell responsesTherapeutic vaccineIntercell AG2012Completed[116]
Virus-like particlesRecombinant HCV-like particles (HCV-LPs) containing core, E1, and E2/AS01B4 chimpanzeesInduce HCV-specific cellular immune responses; viral clearanceProphylactic vaccineNIH2007Published[117]
Recombinant baculovirus containing core, E1 and E2MiceInduce high titers of anti-E2 antibodies and strong HCV-specific cellular immune responses (CD8+ T and Th1 cells)Prophylactic vaccineNIH2001Published[118]
Bacterial-vectored vaccineAttenuated Salmonella typhimurium containing NS3 geneMiceInduce long-lasting T-cell responsesTherapeutic vaccineNIH2001Published[119]
Viral-vectored vaccineRecombinant adenoviral vectors and plasmid DNA expressing NS3-NS5B5 chimpanzeesInduce memory HCV-specific T cells; control of viremiaProphylactic vaccineNIH/Okairos2012Completed[120]
Multiple adenoviral vectors (Ad5, Ad6, Ad24, ChAd32 and ChAd33) expressing NS3-NS5B proteinsMice and rhesus macaqueInduce strong cellular immune responses; long-term maintenance of memory cellsProphylactic vaccineOkairos2006Published[121]
Recombinant vaccinia viruses (rVV) expressing core, E1, E2, P7, NS2 and NS34 chimpanzeesInduce cellular immune responses; reduce viral load; resolve HCV infectionProphylactic vaccineNYC Blood Center2008Published[122]
Recombinant adenoviral vectors (Ad6 and ChAd3) expressing NS3-NS5B proteinsPhase I 40 healthy volunteersInduce sustained HCV-specific T cell responsesProphylactic vaccineOkairos2012Completed[123]
Adenovirus vector (Ad6 and ChAd3) expressing NS3-NS5B proteinsPhase I 36 healthy volunteersHighly immunogenic; induce HCV specific T cell responsesProphylactic vaccineOkairos and Oxford University2009Published[124]
TG4040: MVA vector expressing NS3, NS4 and NS5B proteinsPhase I 15 patients with chronic HCV infectionDecline HCV viral load in 7 of 15 patients associated with T-cell responseTherapeutic vaccineTransgene2009Withdrawn[125]
MVA and ChAd3 vectors expressing NS3, NS4, NS5A and NS5B proteinsPhase I/II Healthy at risk population (68/472 IDU)July 28, 2018: Final data collection dateProphylactic vaccineNIAID2017Ongoing[126]
TG4040 + SOCPhase II 153 patients with chronic HCV infectionInduce HCV- and MVA-specific T-cell responses; develop anti-MVA antibodies; increase rate of early virologic responseTherapeutic vaccine-2014Published[127]
DNA vaccineRecombinant DNA plasmid encoding E22 chimpanzeesInduce humoral and cellular immune responses; resolve the infection; prevent progression to chronicityProphylactic vaccineNIAID/NIH2000Published[128]
Recombinant DNA plasmid and adenovirus vector expressing core, E1, E2 and NS3-58 chimpanzeesInduce HCV-specific T-cell and long-lasting E2-specific antibody responses; reduce viral loadProphylactic vaccineNIH2005Published[129]
Recombinant DNA plasmids and MVA vector expressing core, E1, E2 and NS36 chimpanzeesInduce HCV-specific immune responses; reduce viral load; early control of acute HCV infection; fail to impact on chronicityProphylactic vaccineTransgene2007Published[130]
CIGB-230: Plasmid expressing core/E1/E2 plus recombinant core proteinPhase I 15 non-responder patients with chronic HCV infectionInduce humoral and cellular immune responses; no viral clearanceTherapeutic vaccineUniversity of Montreal + others2009Published[131]
ChronVac-C: Plasmid expressing NS3 and NS4A delivered by in vivo electroporationPhase I/IIa 12 HCV-infected patientsDecline HCV viral load in 4 of 6 patients receiving the highest dose with corresponding HCV-specific T-cell response in 3 patientsTherapeutic vaccineTripep AB2009Recruiting[132]

In the absence of an approved prophylactic vaccine for hepatitis C, reducing exposure to HCV through prevention seems to be the best option. This can be achieved through routine screening of donated blood for HCV markers, providing safe medical procedures, promoting risk-reduction counseling and services for at risk population, increasing public awareness and offering regular HCV testing to high-risk populations with the goal of breaking the cycle of HCV transmission in the society[7,9,82,133]. Despite the so-called improvements in the management of HCV infection, still a long way is ahead to achieve a world free of HCV infection. Here, the remaining challenges to eliminating HCV infection will be discussed.


For many years, IFN-based therapy, despite having frequent side effects, poor tolerability, suboptimal efficacy and prolonged treatment course, was recommended as the standard treatment for HCV infection[134,135]. Introduction of IFN-free DAAs has solved most of these problems in the treatment course of HCV infection. Switch the HCV treatment regimens from IFN-based therapy to DAA therapy is a desirable approach, yet encounter practical barriers such as high price and the restricted accessibility of DAAs[135-138]. Most of the time, the cost of antivirals rather than their effectiveness is the main driver in the treatment decisions. The use of these DAAs is far beyond the financial means of the most-in-need patients especially those who are IFN-intolerant or non-responder. While, equity in health demands that all patients with every socioeconomic status have equitable access to these treatment regimens. Currently, reducing treatment costs and providing DAAs with a relatively high health insurance coverage seem to be best options to improve access to DAA therapy[139].

Accessibility to DAAs, though, by itself is a superb health achievement, still alone might not be sufficient to mitigate the burden of HCV infection. A further challenge is continued transmission of HCV infection in high-risk population specially injecting drug users (IDUs) as the major reservoir of HCV infection[133,137,139]. Considering the fact that most of these infections remain undiagnosed, unidentified HCV-infected IDUs are potential sources for the spread of HCV infection in the society[133,139-141]. While, silent introduction of HCV infection into the community is a serious threat to the national effort to eliminate HCV infection, a threat that will increase with time. Therefore, timely diagnosis of HCV-infected patients through risk-based screening is of the greatest importance[126,133,137]. Screening of blood donations for hepatitis C initiated in the early 1990s has remarkably reduced the risk of HCV transmission through blood transfusion since then. Blood transfusion before the early 1990s was a major contributor to the HCV transmission, but today this risk has become minute[142]. However, it is far, far more difficult to screen IDUs, those who most need risk assessment. Despite the remarkable advantages, the cultural objections hinder screening progress, resulting in low diagnosis rate and, consequently, persistent silent spread of infection. On the other hand, the stigma of injecting drug use makes recognition of all HCV-infected IDUs impossible or logistically difficult at best[133]. In addition, establishment of HCV screening system with a specific focus on IDUs imposes high financial burden on the health system. Given the treatment expenses and dependence of these expenses on the stage of liver disease, screening of all at-risk populations seems much more affordable in a long run. Overall, in addition to interrupting unrecognized transmission of HCV, a part of costs expended in the treatment sector will also be saved with the prompt diagnosis and timely treatment of infected but asymptomatic patients[133,143]. While this process would demand allocation of adequate budgets and resources to integrate routine screening of high-risk population into national health programs.

As another solution, the coverage of needle and syringe exchange program should be expanded to increase the daily access to fresh needles and syringes among IDUs[144]. However, this program has not been very successful to control HCV transmission thus far, as the prevalence of HCV infection among IDUs is on the rise[139]. In fact, the overall focus on syringe sharing as the main vehicle for HCV spread has taken focus away from the other risk behaviors of IDUs such as the shared use of drug ampoules or the other injecting paraphernalia, engagement in high-risk sexual practices and the other drug-related harms[145]. These circumstances create a strong demand for precise surveillance of IDUs to obtain a reliable insight into risk behaviors of IDUs community, and subsequently harm reduction interventions should be tailored to the common risk behaviors among IDUs to mitigate the risk of HCV transmission. In addition, raising general awareness of HCV infection, diagnosis and treatment through public education should be the core activity of any harm reduction intervention, as the root cause of failure in control of HCV infection has been lack of awareness among young drug takers[133,141,146]. The growing number of IDUs and the relatively young age distribution of HCV-infected IDUs have evoke huge attention and provided a good opportunity to drive down the increasing trend of HCV-related mortality in near future through timely interventions and appropriate treatment[139,147].

The changes in HCV genotype distribution attributed to injecting drug use is another challenge in eliminating HCV infection. The changes in genotype distribution are so slight as to be unnoticeable but can have a deep impact on the epidemiology of HCV infection in a long run. These changes merit further attention if we want to properly manage the future burden of HCV infection. Globally, the most prevalent genotype is 1 (46%), followed by 3 (22%), 2 (13%) and 4 (13%)[35,137]. Over the last decade, however, a gradual decrease in the prevalence of genotype 1 and an increase in genotype 3 have been reported due to some changes in the route of transmission, risk factors, source of infection, human migration flow, and age distribution[148,149].

Blood transfusion before 1990 was the most important contributor to the spread of HCV, which has been reflected in the predominance of genotype 1 among older individuals[149,150]. In fact, screening for hepatitis C made blood transfusion remarkably safe since 1990s, paving the way for a gradual increase in the prevalence of genotype 3, which is mostly transmitted by IDU[148-150]. In recent years, IDU has become the main source of HCV transmission[35,137,144,145]. Globally, the estimated number of HCV-infected IDUs is up to 10.0 million (6.0-15.2 million), most of whom are young[35,139,144,147,151]. Meanwhile, the most common risk behavior of IDUs, syringe sharing, is more frequent among young drug injectors than in experienced and long-term injectors[152], amplifying the transmission of HCV among young IDUs population and favoring the continuous increase of HCV genotype 3. In addition to the change in the route of HCV transmission, the ongoing civil strife in the Middle East and the active migration flow from India, Afghanistan and Pakistan, where subtype 3a is endemic, have fuelled the increasing prevalence of genotype 3[148]. On the other hand, death of elderly HCV carriers is slowly driving down the prevalence of HCV genotype 1.

These changes in genotype distribution have profound effects on the prevalence of HCV infection, response to antiviral therapy, cost and duration of treatment, and future burden of HCV infection. Given the higher rates of sustained virological response (SVR) to IFN-based therapy, the first-line therapy in low- and middle-income countries, in patients with HCV genotype 3 as compared to genotype 1[149], an increase in the prevalence of genotype 3 beneficially affects the treatment course both in terms of duration and in terms of cost and brings high benefits on an individual level. However, this increase would impose a greater risk on a population level. In reality the rising prevalence of HCV infection along with the continuous increase in the number of IDUs outweigh this benefit. The disastrous interacting epidemics of HCV infection and IDU are harbinger of a forthcoming public health dilemma, presenting a serious challenge to control transmission of HCV infection. On the other hand, high prevalence of HCV infection among young IDUs is a cause for concern, paving the way for rapid spread of HCV in the community. The old story of hepatitis C has gotten a new scenario. The emergence of IDU as the main risk factor for transmission of HCV is a surrogate in this new scenario. If this scenario is to continue, the emergence of an uncontrollable epidemic of hepatitis C will be expected in the near future.


The global community has always been concerned about the future burden of HCV infection. Although action on this concern has started many years ago with great hopes to eliminate HCV infection, the success remains elusive and will become even more elusive if the current HCV management paradigm is to be continued. We believe that it is now time to reconsider the wisdom of the current management strategies, admit failure, and act with all the strength. If we want to succeed in eliminating HCV infection, a more integrated international effort will be required, involving health policy makers, healthcare practitioners, public health organizations, antiviral drug manufacturers, health insurance companies, and all major stakeholders. In addition, effective prevention, comprehensive screening programs with a specific focus on high-risk population, accessibility to the new anti-HCV treatment regimens and public education should be considered as the top priorities of any health policy decision to eliminate HCV infection. While waiting for a solution, prevalence of HCV infection continues to increase. If we do not want to encounter another uncontrollable public health dilemma, the time to act is now, tomorrow will be very late.


Manuscript source: Invited manuscript

Specialty type: Gastroenterology and hepatology

Country of origin: Iran

Peer-review report classification

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): C, C

Grade D (Fair): D

Grade E (Poor): 0

P- Reviewer: Bock CT, Dang SS, El-Shabrawi M, Sanal MG, Takahashi T S- Editor: Qi Y L- Editor: A E- Editor: Lu YJ

1.  Petruzziello A, Marigliano S, Loquercio G, Cacciapuoti C. Hepatitis C virus (HCV) genotypes distribution: an epidemiological up-date in Europe. Infect Agent Cancer. 2016;11:53.  [PubMed]  [DOI]
2.  Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013;158:329-337.  [PubMed]  [DOI]
3.  Falcón V, Acosta-Rivero N, González S, Dueñas-Carrera S, Martinez-Donato G, Menéndez I, Garateix R, Silva JA, Acosta E, Kourı J. Ultrastructural and biochemical basis for hepatitis C virus morphogenesis. Virus Genes. 2017;53:151-164.  [PubMed]  [DOI]
4.  Yang CHT, Yoo ER, Ahmed A. The Role of Direct-acting Antivirals in the Treatment of Children with Chronic Hepatitis C. J Clin Transl Hepatol. 2017;5:59-66.  [PubMed]  [DOI]
5.  Rehan HS, Manak S, Yadav M; Deepinder, Chopra D, Wardhan N. Diversity of genotype and mode of spread of Hepatitis C virus in Northern India. Saudi J Gastroenterol. 2011;17:241-244.  [PubMed]  [DOI]
6.  Farahat MA, Bahnasy KA, Abdo A, Kamal SM, Kassim SK, Eldin AS. Response Prediction for Chronic HCV Genotype 4 Patients to DAAs. IJACSA. 2016;1:173-178.  [PubMed]  [DOI]
7.  Ferreira PM, Guimarães RA, Souza CM, Guimarães LC, Barros CV, Caetano KA, Rezza G, Spadoni L, Brunini SM. Exposure to hepatitis C virus in homeless men in Central Brazil: a cross-sectional study. BMC Public Health. 2017;17:90.  [PubMed]  [DOI]
8.  Alter MJ. HCV routes of transmission: what goes around comes around. Semin Liver Dis. 2011;31:340-346.  [PubMed]  [DOI]
9.  Omata M, Kanda T, Wei L, Yu ML, Chuang WL, Ibrahim A, Lesmana CR, Sollano J, Kumar M, Jindal A. APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. Hepatol Int. 2016;10:681-701.  [PubMed]  [DOI]
10.  Li Q, Yao Y, Shen Y, Cao D, Li Y, Zhang S, Cun W, Sun M, Yu J, Shi L. Assessment of HCV genotypes in Yunnan Province of Southwest China. Virus Genes. 2017;53:190-196.  [PubMed]  [DOI]
11.  Seto WK, Lai CL, Fung J, Hung I, Yuen J, Young J, Wong DK, Yuen MF. Natural history of chronic hepatitis C: genotype 1 versus genotype 6. J Hepatol. 2010;53:444-448.  [PubMed]  [DOI]
12.  Umumararungu E, Ntaganda F, Kagira J, Maina N. Prevalence of Hepatitis C Virus Infection and Its Risk Factors among Patients Attending Rwanda Military Hospital, Rwanda. Biomed Res Int. 2017;2017:5841272.  [PubMed]  [DOI]
13.  Nepal A, Kunwar B. Evidence of Hepatitis C Virus Infection and Associated Treatment in Nepal. J Mol Biomark Diagn. 2016;7:1000270.  [PubMed]  [DOI]
14.  Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci. 2006;3:47-52.  [PubMed]  [DOI]
15.  Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology. 1997;26:15S-20S.  [PubMed]  [DOI]
16.  Farshadpour F, Raherkhani R. Hepatitis C-related diabetes mellitus: A health dilemma too necessary to consider. Virol Research J. 2016;1:1-2.  [PubMed]  [DOI]
17.  Taherkhani R, Farshadpour F. Epidemiology of hepatitis C virus in Iran. World J Gastroenterol. 2015;21:10790-10810.  [PubMed]  [DOI]
18.  Hwang SJ, Chen LK. Chronic hepatitis C and diabetes mellitus. J Chin Med Assoc. 2006;69:143-145.  [PubMed]  [DOI]
19.  Rouabhia S, Malek R, Bounecer H, Dekaken A, Bendali Amor F, Sadelaoud M, Benouar A. Prevalence of type 2 diabetes in Algerian patients with hepatitis C virus infection. World J Gastroenterol. 2010;16:3427-3431.  [PubMed]  [DOI]
20.  Jadoon NA, Shahzad MA, Yaqoob R, Hussain M, Ali N. Seroprevalence of hepatitis C in type 2 diabetes: evidence for a positive association. Virol J. 2010;7:304.  [PubMed]  [DOI]
21.  Galossi A, Guarisco R, Bellis L, Puoti C. Extrahepatic manifestations of chronic HCV infection. J Gastrointestin Liver Dis. 2007;16:65-73.  [PubMed]  [DOI]
22.  Kartashev V, Döring M, Nieto L, Coletta E, Kaiser R, Sierra S; HCV EuResist Study group. New findings in HCV genotype distribution in selected West European, Russian and Israeli regions. J Clin Virol. 2016;81:82-89.  [PubMed]  [DOI]
23.  Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, Simmonds P. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology. 2014;59:318-327.  [PubMed]  [DOI]
24.  Roman F, Hawotte K, Struck D, Ternes AM, Servais JY, Arendt V, Hoffman P, Hemmer R, Staub T, Seguin-Devaux C. Hepatitis C virus genotypes distribution and transmission risk factors in Luxembourg from 1991 to 2006. World J Gastroenterol. 2008;14:1237-1243.  [PubMed]  [DOI]
25.  Keskın F, Çıftçı S, Türkoğlu S, Badur S. Transmission routes of chronic hepatitis C and their relation to HCV genotypes. Turk J Gastroenterol. 2010;21:396-400.  [PubMed]  [DOI]
26.  Farshadpour F, Makvandi M, Samarbafzadeh AR, Jalalifar MA. Determination of hepatitis C virus genotypes among blood donors in Ahvaz, Iran. Indian J Med Microbiol. 2010;28:54-56.  [PubMed]  [DOI]
27.  Al-Kubaisy W, Al-Naggar RA, Ibrahim NSN, Bobryshev YV, Al-Kubaisy MW. Is dental extraction a risk factor for contracting HCV infection: Abs, RNA and genotype detection. Oral Biol Dentist. 2014;2:7.  [PubMed]  [DOI]
28.  Albenmousa A, Al Obary E, Bzeizi K. Treatment Options for HCV Genotype-4. J Infect Dis Ther. 2016;4:1000266.  [PubMed]  [DOI]
29.  Nouroz F, Shaheen S, Mujtaba G, Noreen S. An overview on hepatitis C virus genotypes and its control. EJMHG. 2015;16:291-298.  [PubMed]  [DOI]
30.  Murphy DG, Sablon E, Chamberland J, Fournier E, Dandavino R, Tremblay CL. Hepatitis C virus genotype 7, a new genotype originating from central Africa. J Clin Microbiol. 2015;53:967-972.  [PubMed]  [DOI]
31.  Ampuero J, Romero-Gómez M, Reddy KR. Review article: HCV genotype 3 - the new treatment challenge. Aliment Pharmacol Ther. 2014;39:686-698.  [PubMed]  [DOI]
32.  Salemovic D, Pesic-Pavlovic I, Jevtovic D, Bojovic K, Ranin J, Brmbolic B, Stanojevic M. Intravenous drug use - an independent predictor for HCV genotypes 3 and 4 infection among HIV/HCV co-infected patients. Arch Med Sci. 2017;13:652-658.  [PubMed]  [DOI]
33.  Chan A, Patel K, Naggie S. Genotype 3 Infection: The Last Stand of Hepatitis C Virus. Drugs. 2017;77:131-144.  [PubMed]  [DOI]
34.  Yee BE, Nguyen NH, Zhang B, Lin D, Vutien P, Wong CR, Lutchman GA, Nguyen MH. Sustained virological response and its treatment predictors in hepatitis C virus genotype 4 compared to genotypes 1, 2, and 3: a meta-analysis. BMJ Open Gastroenterol. 2015;2:e000049.  [PubMed]  [DOI]
35.  Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61:S45-S57.  [PubMed]  [DOI]
36.  Ramia S, Eid-Fares J. Distribution of hepatitis C virus genotypes in the Middle East. Int J Infect Dis. 2006;10:272-277.  [PubMed]  [DOI]
37.  Kanda T, Nakamoto S, Nakamura M, Jiang X, Miyamura T, Wu S, Yokosuka O. Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection. J Clin Transl Hepatol. 2014;2:1-6.  [PubMed]  [DOI]
38.  Bartels DJ, Sullivan JC, Zhang EZ, Tigges AM, Dorrian JL, De Meyer S, Takemoto D, Dondero E, Kwong AD, Picchio G. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment. J Virol. 2013;87:1544-1553.  [PubMed]  [DOI]
39.  Asselah T. A revolution in HCV treatment with direct-acting antivirals: from non-response to eradication. J Hepatol. 2012;57:455-457.  [PubMed]  [DOI]
40.  Tamori A, Enomoto M, Kawada N. Recent Advances in Antiviral Therapy for Chronic Hepatitis C. Mediators Inflamm. 2016;2016:6841628.  [PubMed]  [DOI]
41.  Wyles D, Dvory-Sobol H, Svarovskaia ES, Doehle BP, Martin R, Afdhal NH, Kowdley KV, Lawitz E, Brainard DM, Miller MD. Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir. J Hepatol. 2017;66:703-710.  [PubMed]  [DOI]
42.  Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review. Ann Intern Med. 2017;166:637-648.  [PubMed]  [DOI]
43.  Wang S, Wang Y, Wang J, Sato T, Izawa K, Soloshonok VA, Liu H. The second-generation of highly potent hepatitis C virus (HCV) NS3/4A protease inhibitors: Evolutionary design based on tailor-made amino acids, synthesis and major features of bio-activity. Curr Pharm Des. 2017; Epub ahead of print.  [PubMed]  [DOI]
44.  Alavian SM, Hajarizadeh B, Bagheri Lankarani K, Sharafi H, Ebrahimi Daryani N, Merat S, Mohraz M, Mardani M, Fattahi MR, Poustchi H. Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline. Hepat Mon. 2016;16:e40959.  [PubMed]  [DOI]
45.  Esposito I, Trinks J, Soriano V. Hepatitis C virus resistance to the new direct-acting antivirals. Expert Opin Drug Metab Toxicol. 2016;12:1197-1209.  [PubMed]  [DOI]
46.  Karbalaie Niya MH, Salman-Tabar S, Bokharaei-Salim F, Behmanesh M, Keyvani H. Prevalence of resistant associated variants (RAVs) in the naïve HCV patient candidate for direct acting antiviral (DAA) therapy. Microb Pathog. 2017;105:166-170.  [PubMed]  [DOI]
47.  Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB; American Association for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54:1433-1444.  [PubMed]  [DOI]
48.  Deutsch M, Papatheodoridis GV. Danoprevir, a small-molecule NS3/4A protease inhibitor for the potential oral treatment of HCV infection. Curr Opin Investig Drugs. 2010;11:951-963.  [PubMed]  [DOI]
49.  Guedj J, Dahari H, Shudo E, Smith P, Perelson AS. Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128). Hepatology. 2012;55:1030-1037.  [PubMed]  [DOI]
50.  Greig SL. Sofosbuvir/Velpatasvir: A Review in Chronic Hepatitis C. Drugs. 2016;76:1567-1578.  [PubMed]  [DOI]
51.  Tong L, Yu W, Chen L, Selyutin O, Dwyer MP, Nair AG, Mazzola R, Kim JH, Sha D, Yin J. Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms. J Med Chem. 2017;60:290-306.  [PubMed]  [DOI]
52.  Walker J, Crosby R, Wang A, Woldu E, Vamathevan J, Voitenleitner C, You S, Remlinger K, Duan M, Kazmierski W. Preclinical characterization of GSK2336805, a novel inhibitor of hepatitis C virus replication that selects for resistance in NS5A. Antimicrob Agents Chemother. 2014;58:38-47.  [PubMed]  [DOI]
53.  Adkison KK, Gan J, Elko-Simms L, Gardner S, Dumont E, Jones LS, Saunders J, Marbury T, Smith W, Berg J. Pharmacokinetics of hepatitis C virus NS5A inhibitor JNJ-56914845 (GSK2336805) in subjects with hepatic impairment. J Clin Pharmacol. 2015;55:1042-1050.  [PubMed]  [DOI]
54.  Rodriguez-Torres M, Stoehr A, Gane EJ, Serfaty L, Lawitz E, Zhou A, Bourque M, Bhanja S, Strizki J, Barnard RJ. Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis. Clin Gastroenterol Hepatol. 2014;12:1029-37.e5.  [PubMed]  [DOI]
55.  Gane EJ, Rouzier R, Wiercinska-Drapalo A, Larrey DG, Morcos PN, Brennan BJ, Le Pogam S, Nájera I, Petric R, Tran JQ. Efficacy and safety of danoprevir-ritonavir plus peginterferon alfa-2a-ribavirin in hepatitis C virus genotype 1 prior null responders. Antimicrob Agents Chemother. 2014;58:1136-1145.  [PubMed]  [DOI]
56.  Sarrazin C, Castelli F, Andreone P, Buti M, Colombo M, Pol S, Calinas F, Puoti M, Olveira A, Shiffman M. HCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infection. Clin Exp Gastroenterol. 2016;9:351-363.  [PubMed]  [DOI]
57.  Tao T, Jiang X, Chen Y, Song Y. Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis. Int J Infect Dis. 2017;55:56-71.  [PubMed]  [DOI]
58.  Jensen CM, Holle LM. Ledipasvir-Sofosbuvir: A Once-Daily Oral Treatment Option for Chronic Hepatitis C Virus Genotype 1 Infection. Pharmacotherapy. 2016;36:562-574.  [PubMed]  [DOI]
59.  Sato K, Hosonuma K, Yamazaki Y, Kobayashi T, Takakusagi S, Horiguchi N, Kakizaki S, Kusano M, Ohnishi H, Okamoto H. Combination Therapy with Ombitasvir/Paritaprevir/Ritonavir for Dialysis Patients Infected with Hepatitis C Virus: A Prospective Multi-Institutional Study. Tohoku J Exp Med. 2017;241:45-53.  [PubMed]  [DOI]
60.  Flisiak R, Janczewska E, Wawrzynowicz-Syczewska M, Jaroszewicz J, Zarębska-Michaluk D, Nazzal K, Bolewska B, Bialkowska J, Berak H, Fleischer-Stępniewska K. Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study. Aliment Pharmacol Ther. 2016;44:946-956.  [PubMed]  [DOI]
61.  Calleja JL, Crespo J, Rincón D, Ruiz-Antorán B, Fernandez I, Perelló C, Gea F, Lens S, García-Samaniego J, Sacristán B. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort. J Hepatol. 2017;66:1138-1148.  [PubMed]  [DOI]
62.  Crespo J, Calleja JL, Fernández I, Sacristan B, Ruiz-Antorán B, Ampuero J, Hernández-Conde M, García-Samaniego J, Gea F, Buti M. Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection. Clin Gastroenterol Hepatol. 2017;15:945-949.e1.  [PubMed]  [DOI]
63.  Wilfret DA, Walker J, Adkison KK, Jones LA, Lou Y, Gan J, Castellino S, Moseley CL, Horton J, de Serres M. Safety, tolerability, pharmacokinetics, and antiviral activity of GSK2336805, an inhibitor of hepatitis C virus (HCV) NS5A, in healthy subjects and subjects chronically infected with HCV genotype 1. Antimicrob Agents Chemother. 2013;57:5037-5044.  [PubMed]  [DOI]
64.  Cho BW, Kim SB, Song IH, Lee SH, Kim HS, Lee TH, Kang YW, Kim SH, Lee BS, Chae HB. Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study. Clin Mol Hepatol. 2017;23:51-56.  [PubMed]  [DOI]
65.  Poordad F, Felizarta F, Asatryan A, Sulkowski MS, Reindollar RW, Landis CS, Gordon SC, Flamm SL, Fried MW, Bernstein DE. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. Hepatology. 2017;66:389-397.  [PubMed]  [DOI]
66.  Brieva T, Rivero A, Rivero-Juarez A. Pharmacokinetic drug evaluation of velpatasvir plus sofosbuvir for the treatment of hepatitis C virus infection. Expert Opin Drug Metab Toxicol. 2017;13:483-490.  [PubMed]  [DOI]
67.  Feld JJ, Ramji A, Shafran SD, Willems B, Marotta P, Huchet E, Vachon ML, Svarovskaia ES, Huang KC, Hyland RH. Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study. Clin Infect Dis. 2017; Epub ahead of print.  [PubMed]  [DOI]
68.  Ramos H, Linares P, Badia E, Martín I, Gómez J, Almohalla C, Jorquera F, Calvo S, García I, Conde P. Interferon-free treatments in patients with hepatitis C genotype 1-4 infections in a real-world setting. World J Gastrointest Pharmacol Ther. 2017;8:137-146.  [PubMed]  [DOI]
69.  Wyles DL, Rodriguez-Torres M, Lawitz E, Shiffman ML, Pol S, Herring RW, Massetto B, Kanwar B, Trenkle JD, Pang PS. All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infection. Hepatology. 2014;60:56-64.  [PubMed]  [DOI]
70.  Kanda T, Yokosuka O, Omata M. Faldaprevir for the treatment of hepatitis C. Int J Mol Sci. 2015;16:4985-4996.  [PubMed]  [DOI]
71.  Zeuzem S, Soriano V, Asselah T, Bronowicki JP, Lohse AW, Müllhaupt B, Schuchmann M, Bourlière M, Buti M, Roberts SK. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med. 2013;369:630-639.  [PubMed]  [DOI]
72.  Jensen DM, Brunda M, Elston R, Gane EJ, George J, Glavini K, Hammond JM, Le Pogam S, Nájera I, Passe S. Interferon-free regimens containing setrobuvir for patients with genotype 1 chronic hepatitis C: a randomized, multicenter study. Liver Int. 2016;36:505-514.  [PubMed]  [DOI]
73.  Jiang M, Zhang EZ, Ardzinski A, Tigges A, Davis A, Sullivan JC, Nelson M, Spanks J, Dorrian J, Nicolas O. Genotypic and phenotypic analyses of hepatitis C virus variants observed in clinical studies of VX-222, a nonnucleoside NS5B polymerase inhibitor. Antimicrob Agents Chemother. 2014;58:5456-5465.  [PubMed]  [DOI]
74.  Yi G, Deval J, Fan B, Cai H, Soulard C, Ranjith-Kumar CT, Smith DB, Blatt L, Beigelman L, Kao CC. Biochemical study of the comparative inhibition of hepatitis C virus RNA polymerase by VX-222 and filibuvir. Antimicrob Agents Chemother. 2012;56:830-837.  [PubMed]  [DOI]
75.  Vince B, Hill JM, Lawitz EJ, O’Riordan W, Webster LR, Gruener DM, Mofsen RS, Murillo A, Donovan E, Chen J. A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4. J Hepatol. 2014;60:920-927.  [PubMed]  [DOI]
76.  de Bruijne J, Bergmann JF, Reesink HW, Weegink CJ, Molenkamp R, Schinkel J, Tong X, Li J, Treitel MA, Hughes EA. Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients. Hepatology. 2010;52:1590-1599.  [PubMed]  [DOI]
77.  Lawitz E, Poordad F, Wells J, Hyland RH, Yang Y, Dvory-Sobol H, Stamm LM, Brainard DM, McHutchison JG, Landaverde C. Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus. Hepatology. 2017;65:1803-1809.  [PubMed]  [DOI]
78.  Bourlière M, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M, Ravendhran N, Vierling JM, Tran TT, Pianko S. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. N Engl J Med. 2017;376:2134-2146.  [PubMed]  [DOI]
79.  World Health Organization. Hepatitis C, WHO fact sheet; No. 164, updated April. 2017; Available from:  [PubMed]  [DOI]
80.  Shaheen MA, Idrees M. Evidence-based consensus on the diagnosis, prevention and management of hepatitis C virus disease. World J Hepatol. 2015;7:616-627.  [PubMed]  [DOI]
81.  Helaly GF, Elsheredy AG, El Basset Mousa AA, Ahmed HK, Oluyemi AE. Seronegative and occult hepatitis C virus infections in patients with hematological disorders. Arch Virol. 2017;162:63-69.  [PubMed]  [DOI]
82.  Easterbrook PJ, Roberts T, Sands A, Peeling R. Diagnosis of viral hepatitis. Curr Opin HIV AIDS. 2017;12:302-314.  [PubMed]  [DOI]
83.  Carreño V. Seronegative occult hepatitis C virus infection: clinical implications. J Clin Virol. 2014;61:315-320.  [PubMed]  [DOI]
84.  De Marco L, Manzini P, Trevisan M, Gillio-Tos A, Danielle F, Balloco C, Pizzi A, De Filippo E, D’Antico S, Violante B. Prevalence and follow-up of occult HCV infection in an Italian population free of clinically detectable infectious liver disease. PLoS One. 2012;7:e43541.  [PubMed]  [DOI]
85.  Jain P, Nijhawan S. Occult hepatitis C virus infection is more common than hepatitis B infection in maintenance hemodialysis patients. World J Gastroenterol. 2008;14:2288-2289.  [PubMed]  [DOI]
86.  Carreño V, Bartolomé J, Castillo I, Quiroga JA. New perspectives in occult hepatitis C virus infection. World J Gastroenterol. 2012;18:2887-2894.  [PubMed]  [DOI]
87.  Farshadpour F, Taherkhani R, Tajbakhsh S, Gholizadeh Tangestani M, Hajiani G, Sharifi N, Taherkhani S, Nejadbolkheyr A. Prevalence and Trends of Transfusion-Transmissible Viral Infections among Blood Donors in South of Iran: An Eleven-Year Retrospective Study. PLoS One. 2016;11:e0157615.  [PubMed]  [DOI]
88.  Baumert TF, Fauvelle C, Chen DY, Lauer GM. A prophylactic hepatitis C virus vaccine: a distant peak still worth climbing. J Hepatol. 2014;61:S34-S44.  [PubMed]  [DOI]
89.  Abdelwahab KS, Ahmed Said ZN. Status of hepatitis C virus vaccination: Recent update. World J Gastroenterol. 2016;22:862-873.  [PubMed]  [DOI]
90.  Zingaretti C, De Francesco R, Abrignani S. Why is it so difficult to develop a hepatitis C virus preventive vaccine? Clin Microbiol Infect. 2014;20 Suppl 5:103-109.  [PubMed]  [DOI]
91.  Forns X, Bukh J, Purcell RH. The challenge of developing a vaccine against hepatitis C virus. J Hepatol. 2002;37:684-695.  [PubMed]  [DOI]
92.  Man John Law L, Landi A, Magee WC, Lorne Tyrrell D, Houghton M. Progress towards a hepatitis C virus vaccine. Emerg Microbes Infect. 2013;2:e79.  [PubMed]  [DOI]
93.  Ghasemi F, Rostami S, Meshkat Z. Progress in the development of vaccines for hepatitis C virus infection. World J Gastroenterol. 2015;21:11984-12002.  [PubMed]  [DOI]
94.  Dunlop J, Owsianka A, Cowton V, Patel A. Current and future prophylactic vaccines for hepatitis C virus. Vaccine: Development and Therapy. 2015;2015:31-44.  [PubMed]  [DOI]
95.  Yu CI, Chiang BL. A new insight into hepatitis C vaccine development. J Biomed Biotechnol. 2010;2010:548280.  [PubMed]  [DOI]
96.  Halliday J, Klenerman P, Barnes E. Vaccination for hepatitis C virus: closing in on an evasive target. Expert Rev Vaccines. 2011;10:659-672.  [PubMed]  [DOI]
97.  Naderi M, Gholipour N, Zolfaghari MR, Moradi Binabaj M, Yegane Moghadam A, Motalleb G. Hepatitis C virus and vaccine development. Int J Mol Cell Med. 2014;3:207-215.  [PubMed]  [DOI]
98.  Ogholikhan S, Schwarz KB. Hepatitis Vaccines. Vaccines (Basel). 2016;4:E6.  [PubMed]  [DOI]
99.  Balasco N, Barone D, Sandomenico A, Ruggiero A, Doti N, Berisio R, Ruvo M, Vitagliano L. Structural versatility of hepatitis C virus proteins: implications for the design of novel anti-HCV intervention strategies. Curr Med Chem. 2017; Epub ahead of print.  [PubMed]  [DOI]
100.  Li S, Plebanski M, Smooker P, Gowans EJ. Editorial: Why Vaccines to HIV, HCV, and Malaria Have So Far Failed-Challenges to Developing Vaccines Against Immunoregulating Pathogens. Front Microbiol. 2015;6:1318.  [PubMed]  [DOI]
101.  Choo QL, Kuo G, Ralston R, Weiner A, Chien D, Van Nest G, Han J, Berger K, Thudium K, Kuo C. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci USA. 1994;91:1294-1298.  [PubMed]  [DOI]
102.  Verstrepen BE, Depla E, Rollier CS, Mares G, Drexhage JA, Priem S, Verschoor EJ, Koopman G, Granier C, Dreux M. Clearance of genotype 1b hepatitis C virus in chimpanzees in the presence of vaccine-induced E1-neutralizing antibodies. J Infect Dis. 2011;204:837-844.  [PubMed]  [DOI]
103.  Leroux-Roels G, Depla E, Hulstaert F, Tobback L, Dincq S, Desmet J, Desombere I, Maertens G. A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers. Vaccine. 2004;22:3080-3086.  [PubMed]  [DOI]
104.  Frey SE, Houghton M, Coates S, Abrignani S, Chien D, Rosa D, Pileri P, Ray R, Di Bisceglie AM, Rinella P. Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine. 2010;28:6367-6373.  [PubMed]  [DOI]
105.  Nevens F, Roskams T, Van Vlierberghe H, Horsmans Y, Sprengers D, Elewaut A, Desmet V, Leroux-Roels G, Quinaux E, Depla E. A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology. 2003;38:1289-1296.  [PubMed]  [DOI]
106.  Wedemeyer H, Mazur W, Nevens F, Horsmans Y, Adler M, Blum H, Inglot M, Gerken G, Janczewska E, Roskams T. Factors influencing progression of liver fibrosis in patients with chronic hepatitis C: results of the 3-year T2S-918-HCV study with HCVE1 therapeutic vaccine. J Hepatol. 2008;48:S27-S28.  [PubMed]  [DOI]
107.  Drane D, Maraskovsky E, Gibson R, Mitchell S, Barnden M, Moskwa A, Shaw D, Gervase B, Coates S, Houghton M. Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX vaccine: a phase I study in healthy volunteers. Hum Vaccin. 2009;5:151-157.  [PubMed]  [DOI]
108.  Habersetzer F, Baumert TF, Stoll-Keller F. GI-5005, a yeast vector vaccine expressing an NS3-core fusion protein for chronic HCV infection. Curr Opin Mol Ther. 2009;11:456-462.  [PubMed]  [DOI]
109.  Pockros P, Jacobson I, Boyer TD, Schiff ER, Everson GT, Lee WM, Vierling JM, Lawitz E, Kugelmas M, Tsai N. GI-5005 Therapeutic vaccine plus Peg-IFN/Ribavirin improves sustained virologic response versus Peg-IFN/Ribavirin in prior non-responders with genotype 1 chronic HCV infection. Hepatology. 2010;52:404A-405A.  [PubMed]  [DOI]
110.  Yutani S, Komatsu N, Shichijo S, Yoshida K, Takedatsu H, Itou M, Kuromatu R, Ide T, Tanaka M, Sata M. Phase I clinical study of a peptide vaccination for hepatitis C virus-infected patients with different human leukocyte antigen-class I-A alleles. Cancer Sci. 2009;100:1935-1942.  [PubMed]  [DOI]
111.  Yutani S, Yamada A, Yoshida K, Takao Y, Tamura M, Komatsu N, Ide T, Tanaka M, Sata M, Itoh K. Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy. Vaccine. 2007;25:7429-7435.  [PubMed]  [DOI]
112.  Gowans EJ, Roberts S, Jones K, Dinatale I, Latour PA, Chua B, Eriksson EM, Chin R, Li S, Wall DM. A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals. J Hepatol. 2010;53:599-607.  [PubMed]  [DOI]
113.  Firbas C, Jilma B, Tauber E, Buerger V, Jelovcan S, Lingnau K, Buschle M, Frisch J, Klade CS. Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine. 2006;24:4343-4353.  [PubMed]  [DOI]
114.  Klade CS, Wedemeyer H, Berg T, Hinrichsen H, Cholewinska G, Zeuzem S, Blum H, Buschle M, Jelovcan S, Buerger V. Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology. 2008;134:1385-1395.  [PubMed]  [DOI]
115.  Firbas C, Boehm T, Buerger V, Schuller E, Sabarth N, Jilma B, Klade CS. Immunogenicity and safety of different injection routes and schedules of IC41, a Hepatitis C virus (HCV) peptide vaccine. Vaccine. 2010;28:2397-2407.  [PubMed]  [DOI]
116.  Klade CS, Schuller E, Boehm T, von Gabain A, Manns MP. Sustained viral load reduction in treatment-naive HCV genotype 1 infected patients after therapeutic peptide vaccination. Vaccine. 2012;30:2943-2950.  [PubMed]  [DOI]
117.  Elmowalid GA, Qiao M, Jeong SH, Borg BB, Baumert TF, Sapp RK, Hu Z, Murthy K, Liang TJ. Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc Natl Acad Sci USA. 2007;104:8427-8432.  [PubMed]  [DOI]
118.  Lechmann M, Murata K, Satoi J, Vergalla J, Baumert TF, Liang TJ. Hepatitis C virus-like particles induce virus-specific humoral and cellular immune responses in mice. Hepatology. 2001;34:417-423.  [PubMed]  [DOI]
119.  Wedemeyer H, Gagneten S, Davis A, Bartenschlager R, Feinstone S, Rehermann B. Oral immunization with HCV-NS3-transformed Salmonella: induction of HCV-specific CTL in a transgenic mouse model. Gastroenterology. 2001;121:1158-1166.  [PubMed]  [DOI]
120.  Park SH, Shin EC, Capone S, Caggiari L, De Re V, Nicosia A, Folgori A, Rehermann B. Successful vaccination induces multifunctional memory T-cell precursors associated with early control of hepatitis C virus. Gastroenterology. 2012;143:1048-60.e4.  [PubMed]  [DOI]
121.  Fattori E, Zampaglione I, Arcuri M, Meola A, Ercole BB, Cirillo A, Folgori A, Bett A, Cappelletti M, Sporeno E. Efficient immunization of rhesus macaques with an HCV candidate vaccine by heterologous priming-boosting with novel adenoviral vectors based on different serotypes. Gene Ther. 2006;13:1088-1096.  [PubMed]  [DOI]
122.  Youn JW, Hu YW, Tricoche N, Pfahler W, Shata MT, Dreux M, Cosset FL, Folgori A, Lee DH, Brotman B. Evidence for protection against chronic hepatitis C virus infection in chimpanzees by immunization with replicating recombinant vaccinia virus. J Virol. 2008;82:10896-10905.  [PubMed]  [DOI]
123.  Barnes E, Folgori A, Capone S, Swadling L, Aston S, Kurioka A, Meyer J, Huddart R, Smith K, Townsend R. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med. 2012;4:115ra1.  [PubMed]  [DOI]
124.  Barnes E, Antonella F, Aston S, Smith K, Brown AC, Capone S, Ambrosio M, Ammendola V, Bartiromo M, Traboni C. Phase I trial of a highly immunogenic T-cell vaccine for hepatitis C virus based on novel adenoviral vectors from rare serotypes. Hepatology. 2009;50:397A-398A.  [PubMed]  [DOI]
125.  Habersetzer F, Zarski J-P, Leroy V, Maynard-Muet M, Bronowicki J-P, Feray C, Hezode C, Fournillier A, Bain C, Inchauspe G, Honnet G, Trepo C.  A novel vectorized HCV therapeutic vaccine (TG4040): results of a Phase I study in naive patients chronically infected by HCV. 44th Annual Meeting of the European Association for the Study of the Liver. 2009;April 23-26-Copenhagen, Denmark.  [PubMed]  [DOI]
126.  Page K, Yu M, Cohen J, Evans J, Shumway M, Riley ED. HCV screening in a cohort of HIV infected and uninfected homeless and marginally housed women in San Francisco, California. BMC Public Health. 2017;17:171.  [PubMed]  [DOI]
127.  Di Bisceglie AM, Janczweska-Kazek E, Habersetzer F, Mazur W, Stanciu C, Carreno V, Tanasescu C, Flisiak R, Romero-Gomez M, Fich A. Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a Phase 2 study of patients with chronic HCV infection. Gastroenterology. 2014;147:119-131.e3.  [PubMed]  [DOI]
128.  Forns X, Payette PJ, Ma X, Satterfield W, Eder G, Mushahwar IK, Govindarajan S, Davis HL, Emerson SU, Purcell RH. Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV. Hepatology. 2000;32:618-625.  [PubMed]  [DOI]
129.  Youn JW, Park SH, Lavillette D, Cosset FL, Yang SH, Lee CG, Jin HT, Kim CM, Shata MT, Lee DH. Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee. Hepatology. 2005;42:1429-1436.  [PubMed]  [DOI]
130.  Rollier CS, Paranhos-Baccala G, Verschoor EJ, Verstrepen BE, Drexhage JA, Fagrouch Z, Berland JL, Komurian-Pradel F, Duverger B, Himoudi N. Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity. Hepatology. 2007;45:602-613.  [PubMed]  [DOI]
131.  Alvarez-Lajonchere L, Shoukry NH, Grá B, Amador-Cañizares Y, Helle F, Bédard N, Guerra I, Drouin C, Dubuisson J, González-Horta EE. Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial. J Viral Hepat. 2009;16:156-167.  [PubMed]  [DOI]
132.  Sallberg M, Frelin L, Diepolder H, Jung MC, Mathiesen I, Fons M, Hultcrantz R, Carlsson T, Weiland O.  A first clinical trial of therapeutic vaccination using naked DNA delivered by in vivo electroporation shows antiviral effects in patients with chronic hepatitis C. 44th Annual Meeting of the European Association for the Study of the Liver;. 2009;April 23-26; Copenhagen, Denmark.  [PubMed]  [DOI]
133.  Dillon JF, Lazarus JV, Razavi HA. Urgent action to fight hepatitis C in people who inject drugs in Europe. Hepatol Med Policy. 2016;1:2.  [PubMed]  [DOI]
134.  Kottilil S, Wright M, Polis MA, Masur H. Treatment of hepatitis C virus infection: is it time for the internist to take the reins? Ann Intern Med. 2014;161:443-444.  [PubMed]  [DOI]
135.  Seo KI, Yun BC, Li WJ, Lee SU, Han BH, Park ET. Barriers to treatment of failed or interferon ineligible patients in the era of DAA: single center study. Clin Mol Hepatol. 2017;23:74-79.  [PubMed]  [DOI]
136.  McCance-Katz EF, Valdiserri RO. Hepatitis C Virus Treatment and Injection Drug Users: It Is Time to Separate Fact From Fiction. Ann Intern Med. 2015;163:224-225.  [PubMed]  [DOI]
137.  Robaeys G, Bielen R, Azar DG, Razavi H, Nevens F. Global genotype distribution of hepatitis C viral infection among people who inject drugs. J Hepatol. 2016;65:1094-1103.  [PubMed]  [DOI]
138.  Lim SG, Aghemo A, Chen PJ, Dan YY, Gane E, Gani R, Gish RG, Guan R, Jia JD, Lim K. Management of hepatitis C virus infection in the Asia-Pacific region: an update. Lancet Gastroenterol Hepatol. 2017;2:52-62.  [PubMed]  [DOI]
139.  Moradpour D, Grakoui A, Manns MP. Future landscape of hepatitis C research - Basic, translational and clinical perspectives. J Hepatol. 2016;65:S143-S155.  [PubMed]  [DOI]
140.  Grebely J, Bruggmann P, Treloar C, Byrne J, Rhodes T, Dore GJ; International Network for Hepatitis in Substance Users. Expanding access to prevention, care and treatment for hepatitis C virus infection among people who inject drugs. Int J Drug Policy. 2015;26:893-898.  [PubMed]  [DOI]
141.  Taherkhani R, Farshadpour F. Lurking epidemic of hepatitis C virus infection in Iran: A call to action. World J Hepatol. 2017;9:1040-1042.  [PubMed]  [DOI]
142.  Moyer VA; U. S. Preventive Services Task Force. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;159:349-357.  [PubMed]  [DOI]
143.  Aggarwal R, Chen Q, Goel A, Seguy N, Pendse R, Ayer T, Chhatwal J. Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India. PLoS One. 2017;12:e0176503.  [PubMed]  [DOI]
144.  Davis SM, Daily S, Kristjansson AL, Kelley GA, Zullig K, Baus A, Davidov D, Fisher M. Needle exchange programs for the prevention of hepatitis C virus infection in people who inject drugs: a systematic review with meta-analysis. Harm Reduct J. 2017;14:25.  [PubMed]  [DOI]
145.  Midgard H, Weir A, Palmateer N, Lo Re V 3rd, Pineda JA, Macías J, Dalgard O. HCV epidemiology in high-risk groups and the risk of reinfection. J Hepatol. 2016;65:S33-S45.  [PubMed]  [DOI]
146.  U.S. Department of Health and Human Services. Combating the Silent Epidemic of Viral Hepatitis: Action Plan for the Prevention, Care, and Treatment of Viral Hepatitis. Technical consultation: hepatitis C virus infection in young persons who inject drugs. 2013.  Available from:  [PubMed]  [DOI]
147.  Grebely J, Dore GJ. Prevention of hepatitis C virus in injecting drug users: a narrow window of opportunity. J Infect Dis. 2011;203:571-574.  [PubMed]  [DOI]
148.  Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61:77-87.  [PubMed]  [DOI]
149.  Dias PT, Hahn JA, Delwart E, Edlin B, Martin J, Lum P, Evans J, Kral A, Deeks S, Busch MP. Temporal changes in HCV genotype distribution in three different high risk populations in San Francisco, California. BMC Infect Dis. 2011;11:208.  [PubMed]  [DOI]
150.  Yan Z, Fan K, Wang Y, Fan Y, Tan Z, Deng G. Changing pattern of clinical epidemiology on hepatitis C virus infection in southwest china. Hepat Mon. 2012;12:196-204.  [PubMed]  [DOI]
151.  Morris MD, Shiboski S, Bruneau J, Hahn JA, Hellard M, Prins M, Cox AL, Dore G, Grebely J, Kim AY, Lauer GM, Lloyd A, Rice T, Shoukry N, Maher L, Page K; International Collaboration of Incident HIV and HCV in Injecting Cohorts (InC3). Geographic Differences in Temporal Incidence Trends of Hepatitis C Virus Infection Among People Who Inject Drugs: The InC3 Collaboration. Clin Infect Dis. 2017;64:860-869.  [PubMed]  [DOI]
152.  Oliveira ML, Yoshida CF, Telles PR, Hacker MA, Oliveira SA, Miguel JC, do O KM, Bastos FI. Trends in HCV prevalence, risk factors and distribution of viral genotypes in injecting drug users: findings from two cross-sectional studies. Epidemiol Infect. 2009;137:970-979.  [PubMed]  [DOI]